Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2024 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study.
de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, Guchelaar HJ, Verheul HM, Gelderblom H. de Wit D, et al. Ther Drug Monit. 2015 Jun;37(3):331-8. doi: 10.1097/FTD.0000000000000141. Ther Drug Monit. 2015. PMID: 25271729 Clinical Trial.
The primary objective of this study was to evaluate the feasibility of pharmacokinetics (PK)-guided individualized dosing to reduce the interpatient variability in pazopanib exposure. ...CONCLUSIONS: PK-guided dosing did not reduce …
The primary objective of this study was to evaluate the feasibility of pharmacokinetics (PK)-guided individualized …
Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort.
Meertens M, Giraud EL, van der Kleij MBA, Westerdijk K, Guchelaar NAD, Bleckman RF, Rieborn A, Imholz ALT, Otten HM, Vulink A, Los M, Hamberg P, van der Graaf WTA, Gelderblom H, Moes DJAR, Broekman KE, Touw DJ, Koolen SLW, Mathijssen RHJ, Huitema ADR, van Erp NP, Desar IME, Steeghs N; Dutch Pharmacology Oncology Group (DPOG). Meertens M, et al. Clin Pharmacokinet. 2024 Jul;63(7):1045-1054. doi: 10.1007/s40262-024-01399-8. Epub 2024 Jul 16. Clin Pharmacokinet. 2024. PMID: 39012619 Free PMC article.
Its variable pharmacokinetic (PK) characteristics and narrow therapeutic range provide a strong rationale for therapeutic drug monitoring (TDM). ...This study investigates the effect of TDM of pazopanib in patients with STS on surv …
Its variable pharmacokinetic (PK) characteristics and narrow therapeutic range provide a strong rationale for therapeutic …
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Lankheet NAG, Desar IME, Mulder SF, Burger DM, Kweekel DM, van Herpen CML, van der Graaf WTA, van Erp NP. Lankheet NAG, et al. Br J Clin Pharmacol. 2017 Oct;83(10):2195-2204. doi: 10.1111/bcp.13327. Epub 2017 Jul 4. Br J Clin Pharmacol. 2017. PMID: 28500677 Free PMC article.
The aim of this study was to monitor how many patients reached adequate trough levels after therapeutic drug monitoring-based dose optimization in daily practice. ...Therapeutic drug monitoring may add to the improvement of efficac …
The aim of this study was to monitor how many patients reached adequate trough levels after therapeutic drug monitor …